Detalhe da pesquisa
1.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Cell
; 171(4): 934-949.e16, 2017 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29033130
2.
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Lancet Oncol
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38608691
3.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
N Engl J Med
; 374(26): 2542-52, 2016 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27093365
4.
BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
Int J Cancer
; 140(12): 2716-2727, 2017 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27342756
5.
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Oncologist
; 22(6): 709-718, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28495807
6.
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Gastroenterology
; 160(3): 932-934.e3, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33096100
7.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med
; 366(26): 2443-54, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658127
8.
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
J Transl Med
; 13: 214, 2015 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26143264
9.
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
J Immunother Cancer
; 12(3)2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38458639
10.
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
J Clin Oncol
; 42(9): 1011-1020, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38252910
11.
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
J Clin Oncol
; 41(5): 943-954, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36750016
12.
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
J Clin Oncol
; 41(4): 715-723, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706735
13.
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.
Oncologist
; 22(6): 627-630, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576858
14.
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics.
J Am Acad Dermatol
; 64(6): 1051-9, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21255868
15.
Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.
Cancer Biol Ther
; 22(10-12): 513-526, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26418961
16.
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.
Oncoimmunology
; 10(1): 1984059, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34650833
17.
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
J Immunother Cancer
; 9(6)2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083421
18.
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
Melanoma Res
; 31(1): 67-75, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33234846
19.
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
J Immunother Cancer
; 9(4)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33879601
20.
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
J Clin Oncol
; 38(22): 2476-2487, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32324435